EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

IgA nephropathy in adults—treatment standard

Patrick J Gleeson, Michelle M O'Shaughnessy iD, Jonathan Barratt

Nephrology Dialysis Transplantation · 31.10.2023 · 38 (11) · 2464-2473

DOI: 10.1093/ndt/gfad146 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Nephrology Dialysis Transplantation, online erschienen am 07.07.2023. Verfasst von Patrick J Gleeson und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Renal Medicine, Cork University Hospital, Cork, Ireland. Hauptthemen laut MEDLINE: Glomerulonephritis, IGA. Die Arbeit wurde bisher 69-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immunoglobulin A nephropathy (IgAN) is the most common primary form of glomerular disease worldwide and carries a high lifetime risk of kidney failure. The underlying pathogenesis of IgAN has been characterized to a sub-molecular level; immune complexes containing specific O-glycoforms of IgA1 are central. Kidney biopsy remains the gold-standard diagnostic test for IgAN and histological features (i.e. MEST-C score) have also been shown to independently predict outcome. Proteinuria and blood pressure are the main modifiable risk factors for disease progression. No IgAN-specific biomarker has yet been validated for diagnosis, prognosis or tracking response to therapy. There has been a recent resurgence of investigation into IgAN treatments. Optimized supportive care with lifestyle interventions and non-immunomodulatory drugs remains the backbone of IgAN management. The menu of available reno-protective medications is rapidly expanding beyond blockade of the renin–angiotensin–aldosterone system to include sodium-glucose cotransporter 2 and endothelin type A receptor antagonism. Systemic immunosuppression can further improve kidney outcomes, although recent randomized controlled trials have raised concerns regarding infectious and metabolic toxicity from systemic corticosteroids. Studies evaluating more refined approaches to immunomodulation in IgAN are ongoing: drugs targeting the mucosal immune compartment, B-cell promoting cytokines and the complement cascade are particularly promising. We review the current standards of treatment and discuss novel developments in pathophysiology, diagnosis, outcome prediction and management of IgAN.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glomerulonephritis, IGAAdultHumansKidneyImmunoglobulin APrognosisProteinuria

Stichwörter der Autor:innen

IgA nephropathydiagnosispathophysiologyprognosistreatment

Substanzen

Immunoglobulin A

Autor:innen und Institutionen

  • Department of Renal Medicine, Cork University Hospital, Cork, Ireland.
  • Department of Medicine, School of Microbiology, APC Microbiome Ireland, University College Cork, Cork, Ireland.
  • Department of Nephrology, Galway University Hospitals, Galway, Ireland.
  • The Mayer IgA Nephropathy Laboratories, University of Leicester, Leicester, UK.

ORCID-Profile: Michelle M O'Shaughnessy

Zitieren

APA

Gleeson, P. J., O'Shaughnessy, M. M., & Barratt, J. (2023). IgA nephropathy in adults—treatment standard. Nephrology Dialysis Transplantation, 38(11), 2464-2473. https://doi.org/10.1093/ndt/gfad146

Vancouver

Gleeson PJ, O'Shaughnessy MM, Barratt J. IgA nephropathy in adults—treatment standard. Nephrology Dialysis Transplantation. 2023;38(11):2464-2473. doi:10.1093/ndt/gfad146

BibTeX
@article{Gleeson2023,
  author = {Gleeson, Patrick J and O'Shaughnessy, Michelle M and Barratt, Jonathan},
  title = {IgA nephropathy in adults—treatment standard},
  journal = {Nephrology Dialysis Transplantation},
  year = {2023},
  volume = {38},
  number = {11},
  pages = {2464--2473},
  doi = {10.1093/ndt/gfad146}
}
Kostenlos starten →